LigaChem Biosciences Inc.

As of March 31, 2026, LigaChem Biosciences Inc. carries a market capitalization of 7.00T, placing it among publicly traded companies globally. Its enterprise value stands at 6.61T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

LigaChem Biosciences Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, LigaChem Biosciences Inc. has 36.44M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 55.49, and the price-to-book ratio stands at 15.11.

These figures are as of March 31, 2026. The EV/Sales ratio of 52.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.61T versus a market cap of 7.00T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, LigaChem Biosciences Inc. maintains a current ratio of 10.12, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.52, indicating moderate leverage, while an interest coverage ratio of -92.98 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, LigaChem Biosciences Inc. posted a negative return on equity (ROE) of -26.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.83, reflecting losses generated across the asset base. The company generates approximately 711.11M in revenue per employee across its workforce of 177.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 86.24 indicates how many times LigaChem Biosciences Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, LigaChem Biosciences Inc. recorded an income tax benefit of -3.31B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -154.64B and -138.08B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, LigaChem Biosciences Inc.'s stock has declined approximately 49.18% over the past 52 weeks. The 50-day moving average sits at 87,856.00, while the 200-day moving average is 144,829.50.

Over the twelve months ended March 31, 2026, LigaChem Biosciences Inc. generated 125.87B in revenue and converted that into -138.08B in net income, yielding earnings per share of -4,159.82. EBITDA reached -148.44B, while operating income came in at -155.28B.

As of March 31, 2026, LigaChem Biosciences Inc. holds 428.34B in cash and equivalents against 2.60B in total debt, resulting in a net debt position of -63.48B. Total book value stands at 462.98B, with working capital of 432.53B providing operational flexibility.

LigaChem Biosciences Inc. produced -140.52B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -6.18B in capital expenditures, free cash flow totaled -146.70B - equivalent to -4,032.52 per share.

Over the twelve months ended March 31, 2026, LigaChem Biosciences Inc. posted a gross margin of 88.94, reflecting its pricing power and cost economics. The operating margin of -123.37 and net profit margin of -109.71 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -2.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.03, meaning LigaChem Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

LigaChem Biosciences Inc.'s most recent stock split took place on June 16, 2020 with a 1:2 split ratio.

As of March 31, 2026, LigaChem Biosciences Inc. has an Altman Z-Score of 28.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.